Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[3]
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[4]
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ US 20100260769, Sass PM, Kline B, Nicolaides N, Grasso L, Harley S, "Endosialin binding molecules", published 2010-04-08, assigned to Morphotek Inc
- ^ Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. (August 2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
- ^ a b "Ontuxizumab". Adis Insight. Springer Nature Switzerland AG.
You must be logged in to post a comment.